Unknown

Dataset Information

0

M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition.


ABSTRACT: Highly selective positive allosteric modulators (PAMs) of the M1 subtype of muscarinic acetylcholine receptor have emerged as an exciting new approach for improving cognitive function in patients suffering from Alzheimer's disease and schizophrenia. However, excessive activation of M1 is known to induce seizure activity and have actions in the prefrontal cortex (PFC) that could impair cognitive function. We now report a series of pharmacological, electrophysiological, and behavioral studies in which we find that recently reported M1 PAMs, PF-06764427 and MK-7622, have robust agonist activity in cell lines and agonist effects in the mouse PFC, and have the potential to overactivate the M1 receptor and disrupt PFC function. In contrast, structurally distinct M1 PAMs (VU0453595 and VU0550164) are devoid of agonist activity in cell lines and maintain activity dependence of M1 activation in the PFC. Consistent with the previously reported effect of PF-06764427, the ago-PAM MK-7622 induces severe behavioral convulsions in mice. In contrast, VU0453595 does not induce behavioral convulsions at doses well above those required for maximal efficacy in enhancing cognitive function. Furthermore, in contrast to the robust efficacy of VU0453595, the ago-PAM MK-7622 failed to improve novel object recognition, a rodent assay of cognitive function. These findings suggest that in vivo cognition-enhancing efficacy of M1 PAMs can be observed with PAMs lacking intrinsic agonist activity and that intrinsic agonist activity of M1 PAMs may contribute to adverse effects and reduced efficacy in improving cognitive function.

SUBMITTER: Moran SP 

PROVIDER: S-EPMC6006294 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

M<sub>1</sub>-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition.

Moran Sean P SP   Dickerson Jonathan W JW   Cho Hyekyung P HP   Xiang Zixiu Z   Maksymetz James J   Remke Daniel H DH   Lv Xiaohui X   Doyle Catherine A CA   Rajan Deepa H DH   Niswender Colleen M CM   Engers Darren W DW   Lindsley Craig W CW   Rook Jerri M JM   Conn P Jeffrey PJ  

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20180314 8


Highly selective positive allosteric modulators (PAMs) of the M<sub>1</sub> subtype of muscarinic acetylcholine receptor have emerged as an exciting new approach for improving cognitive function in patients suffering from Alzheimer's disease and schizophrenia. However, excessive activation of M<sub>1</sub> is known to induce seizure activity and have actions in the prefrontal cortex (PFC) that could impair cognitive function. We now report a series of pharmacological, electrophysiological, and b  ...[more]

Similar Datasets

| S-EPMC5253171 | biostudies-literature
| S-EPMC3558808 | biostudies-literature
| S-EPMC9077236 | biostudies-literature
| S-EPMC5368958 | biostudies-literature
| S-EPMC3969087 | biostudies-other
| S-EPMC5842153 | biostudies-literature
| S-EPMC6456254 | biostudies-literature
| S-EPMC4443790 | biostudies-literature
| S-EPMC3696790 | biostudies-literature
| S-EPMC5130132 | biostudies-literature